Cavedon Elisabetta, Barollo Susi, Bertazza Loris, Pennelli Gianmaria, Galuppini Francesca, Watutantrige-Fernando Sara, Censi Simona, Iacobone Maurizio, Benna Clara, Vianello Federica, Zovato Stefania, Nacamulli Davide, Mian Caterina
Familial Tumor Unit, Veneto Institute of Oncology, (IOV)-IRCCS, Padova, Italy.
Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Int J Endocrinol. 2017;2017:4915736. doi: 10.1155/2017/4915736. Epub 2017 Jun 6.
Little is known about the function of microRNA-224 (miR-224) in medullary thyroid cancer (MTC). This study investigated the role of miR-224 expression in MTC and correlated it with mutation status in sporadic MTCs. A consecutive series of 134 MTCs were considered. Patients had a sporadic form in 80% of cases (107/134). In this group, REarranged during transfection () and rat sarcoma () mutation status were assessed by direct sequencing in the tumor tissues. Quantitative real-time polymerase chain reaction was used to quantify mature hsa-miR-224 in tumor tissue. (10/107 cases, 9%) and (39/107 cases, 36%) mutations were mutually exclusive in sporadic cases. miR-224 expression was significantly downregulated in patients with the following: high calcitonin levels at diagnosis ( = 0.03, = -0.3); advanced stage ( = 0.001); persistent disease ( = 0.001); progressive disease ( = 0.002); and disease-related death ( = 0.0001). We found a significant positive correlation between miR-224 expression and somatic mutations ( = 0.007). Patients whose MTCs had a low miR-224 expression tended to have a shorter overall survival (log-rank test = 0.005). On multivariate analysis, miR-224 represented an independent prognostic marker. Our data indicate that miR-224 is upregulated in -mutated MTCs and in patients with a better prognosis and could represent an independent prognostic marker in MTC patients.
关于微小RNA-224(miR-224)在甲状腺髓样癌(MTC)中的功能,人们所知甚少。本研究调查了miR-224表达在MTC中的作用,并将其与散发性MTC的突变状态相关联。纳入了连续的134例MTC患者。80%的病例(107/134)为散发性。在该组中,通过对肿瘤组织进行直接测序来评估转染重排(RET)和大鼠肉瘤(RAS)突变状态。采用定量实时聚合酶链反应来定量肿瘤组织中成熟的人miR-224。在散发性病例中,RET(10/107例,9%)和RAS(39/107例,36%)突变相互排斥。miR-224表达在以下患者中显著下调:诊断时降钙素水平高(P = 0.03,r = -0.3);晚期(P = 0.001);持续性疾病(P = 0.001);进行性疾病(P = 0.002);以及疾病相关死亡(P = 0.0001)。我们发现miR-224表达与体细胞RET突变之间存在显著正相关(P = 0.007)。MTC中miR-224表达低的患者总体生存期往往较短(对数秩检验P = 0.005)。多因素分析显示,miR-224是一个独立的预后标志物。我们的数据表明,miR-224在RET突变的MTC患者以及预后较好的患者中上调,并且可能是MTC患者的一个独立预后标志物。